PRESS RELEASE
January 31, 2020
During January, the registered number of shares and votes in Saniona AB (publ) ("Saniona") has increased due to the directed issue of shares resolved by the board of directors on January 10, 2020. As of January 31, 2020, the registered number of shares and votes in Saniona amounts to 29,412,519.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona. Mobile: +45 2210 9957, E-mail: tf@saniona.com
This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on January 31, 2020.
About Saniona
Saniona is a rare disease biotechnology company focused on research and development company focused on drugs for treatment of eating disorders and diseases of the central nervous system. The Company has five programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the Company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the Company's shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Attachment
- 20200131 - PR - Increase number of shares - UK (https://ml-eu.globenewswire.com/Resource/Download/ba676310-ac98-436d-84e5-b46082ecd934)
